Clinical Trials on Hematologic Malignancy in New Zealand

Total 3425 results

National Institute of Neurological Disorders and...

Completed

Treatment of AIDS Vacuolar Myelopathy With Methionine

Myelopathy | AIDS-Myelopathy | AIDS Vacuolar Myelopathy

United States
The Canadian Blood and Marrow Transplant Group
National Cancer Institute (NCI)

Completed

Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Graft Versus Host Disease | Secondary Myelofibrosis

Australia, Canada, United States, New Zealand, Saudi Arabia
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer

Carcinoma | Malignant Neoplasm | Surgical Procedure, Unspecified | Health Care Provider

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Dana-Farber Cancer Institute

Completed

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Endometrial Cancer | Desmoid Tumor | Adult Malignant Fibrous Histiocytoma of Bone

United States
Humanigen, Inc.

Suspended

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Myelodysplastic Syndrome (MDS) | Myelofibrosis (MF)

United States, Australia
Icahn School of Medicine at Mount Sinai
Dompé Farmaceutici S.p.A

Recruiting

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Myelofibrosis (PMF) | Post Essential Thrombocythemia Myelofibrosis (ET-MF) | Post Polycythemia Vera Related Myelofibrosis (PV-MF)

United States
John Mascarenhas
National Cancer Institute (NCI); Formation Biologics; Myeloproliferative Neoplasm...

Completed

MPN-RC 118 AVID200 in Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis | Post ET MF | Post PV MF

United States
Cornell University
University of Rochester

Completed

Absorption of Heme and Non-Heme Iron in Pregnant and Non-pregnant Women and Mechanisms of Fetal Iron Transfer

Iron Deficiency

United States
Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Terminated

S9624 Ifosfamide in Treating Patients With Meningeal Tumors

Chondrosarcoma | Adult Rhabdomyosarcoma | Adult Fibrosarcoma | Adult Leiomyosarcoma | Adult Malignant Meningioma | Adult Brain Malignant Hemangiopericytoma

United States, Australia, Peru, Puerto Rico
AMAG Pharmaceuticals, Inc.

Completed

A Crossover Safety Study of Ferumoxytol Versus Placebo

Anemia

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Recurrent Pleural Malignant Mesothelioma | Stage IV Pleural Mesothelioma

United States
Memorial Sloan Kettering Cancer Center
University of Pennsylvania; Dana-Farber Cancer Institute; Novartis Pharmaceuticals

Completed

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Malignant Pleural Mesothelioma

United States
Abbott

Completed

Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain

Moderate to Severe Chronic, Non-malignant Pain

United States
Kadmon Corporation, LLC

Terminated

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

HER-2 Positive Breast Cancer | Metastatic Malignant Neoplasm to Brain

United States
Synthekine

Recruiting

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | NHL | CLL/SLL | Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Synta Pharmaceuticals Corp.

Completed

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

Myeloproliferative Disorders | AML | MDS | CML

United States
Cellenkos, Inc.

Recruiting

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs (TREG108)

Myelofibrosis

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

Sarcoma | Childhood Malignant Fibrous Histiocytoma of Bone

United States
Ruhr University of Bochum

Completed

Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma

Cutaneous Malignant Melanoma

Germany
BioAge Labs, Inc.

Withdrawn

Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging

Anemia

Australia
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Completed

Confocal Reflectance Microscopy of Shave-Biopsy Sites on Skin in Vivo.

Melanoma | Basal Cell Carcinoma | Squamous Cell Carcinoma | Non-Malignant Skin Disorders

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Liver | Metastatic Breast Carcinoma | Metastatic Malignant Neoplasm in the Lung and other conditions

United States, Canada, Saudi Arabia, Korea, Republic of
University of Rochester

Recruiting

A Patient-Centered Communication Tool (UR-GOAL) Versus Usual Care for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists (UR-GOAL 2)

Acute Myeloid Leukemia

United States
Medivation, Inc.

Completed

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Melanoma | Malignant Melanoma

United States, Israel
University of Rochester

Terminated

Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements.

Blood Coagulation Disorder

United States
University of Rochester

Completed

A Patient-centered Communication Tool (UR-GOAL) for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists

Acute Myeloid Leukemia

United States
Otsuka Australia Pharmaceutical Pty Ltd

Completed

Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire (TPMQ)

Myelodysplastic Syndrome (MDS)

Australia
Yale University

Withdrawn

CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.

MDS

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma

Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Dermatofibrosarcoma Protuberans | Adult Angiosarcoma | Adult Epithelioid Sarcoma | Adult Extraskeletal Osteosarcoma | Adult Fibrosarcoma | Adult Leiomyosarcoma and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico
Centers for Disease Control and Prevention

Completed

Treatment and Management of Women With Bleeding Disorders

Blood Coagulation Disorders | Blood Platelet Disorders | Menorrhagia | Hematologic Disease | Von Willebrand Disease

United States
TScan Therapeutics, Inc.

Recruiting

A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation

Myelodysplastic Syndromes | AML | ALL, Adult

United States
Celgene
Agios Pharmaceuticals, Inc.

Completed

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Hematologic Neoplasms

United States, France
Genmab

Recruiting

GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies

Acute Myeloid Leukemia (AML) | Diffuse Large B Cell Lymphoma (DLBCL) | Relapsed or Refractory Multiple Myeloma (RRMM)

United States, Korea, Republic of, Netherlands, Denmark, Australia, New Zealand, Poland, Spain, Sweden, Czechia, Malaysia, Greece, Moldova, Republic of, Georgia, Ukraine, France, Hungary, North Macedonia, Bosnia and Herzegovina
Immunocore Ltd

Completed

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Malignant Melanoma

United Kingdom, United States
Prelude Therapeutics

Completed

A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Non Hodgkin Lymphoma

United States
Pfizer

Terminated

First in Patient Study for PF-06840003 in Malignant Gliomas

Astrocytoma | Malignant Glioma | Oligodendroglioma

United States
Watson Pharmaceuticals

Completed

Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients

Anemia

United States
Weill Medical College of Cornell University
Sunesis Pharmaceuticals

Completed

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

Myelodysplastic Syndrome

United States
Weill Medical College of Cornell University

Completed

Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML

Myelodysplastic Syndrome

United States
Weill Medical College of Cornell University
Celgene

Terminated

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Weill Medical College of Cornell University
CTI BioPharma

Completed

Study of Clinical Efficacy and Safety of Tosedostat in MDS (IST-CTI-MDS)

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Withdrawn

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
H. Lee Moffitt Cancer Center and Research Institute
Blueprint Medicines Corporation

Recruiting

Avapritinib With Decitabine in Patients With SM-AHN

Systemic Mastocytosis With an Associated Hematologic Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Columbia University; Karyopharm Therapeutics Inc

Completed

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Columbia University
Celgene Corporation

Active, not recruiting

Revlimid in Transfusion Dependent Patients

Myelodysplastic Syndrome

United States
Weill Medical College of Cornell University

Terminated

Use of Cast Iron Pots to Improve Maternal Anemia

Iron-deficiency Anemia

United States
Onconova Therapeutics, Inc.

Withdrawn

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Myelodysplastic Syndrome

United States
Columbia University
Grifols Therapeutics LLC

Completed

Intravenous Immunoglobulin (IVIG) in Lung Transplantation

Lung Transplantation | Hypogammaglobulinemia

United States
David M. Simpson
CSL Behring

Terminated

A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy

HIV-associated Myelopathy

United States

Clinical Trials on Hematologic Malignancy in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations